Literature DB >> 33419765

Intrinsic Abnormalities of Keratinocytes Initiate Skin Inflammation through the IL-23/T17 Axis in a MALT1-Dependent Manner.

Shanshan Zhang1,2, Mingchao Wang2,3, Chenliang Wang1,2,3, Guifen Wang1,2, Keyong Sun2, Sihan Xiong1,2, Liqing Cheng1,2,3, Dandan Yang1,2, Xin Lin4,2,3, Xueqiang Zhao4,2.   

Abstract

Increasing evidence has supported the crucial role of CARD14 in the pathogenesis of psoriasis, whereas the precise cellular signaling involved in skin physiopathology remains poorly understood. In this article, we show that neither genetic ablation of Il17a nor elimination of T cells was sufficient to restrain the skin inflammation in a CARD14-E138A-mutation-induced psoriasis-like mouse model, whereas depletion of Il23, which extremely blocked the IL-23/T17 axis, was more effective. Targeting CBM complex by conditional deletion of MALT1 or BCL10 in keratinocytes abrogated both the cutaneous and systemic inflammation of heterozygous Card14 E138A/+ mice. Selective inactivation of keratinocyte-specific MALT1 proteolytic activity strongly ameliorated the Card14 E138A/+- and Card14 ΔQ136/+-induced skin disease, which was reproduced by using the imiquimod-induced mouse model. Together, our results suggest a sequence of events under CARD14-mutation-induced psoriasis condition that keratinocyte-intrinsic activation of CBM complex initiates the skin inflammation depending on the IL-23/T17 axis. Targeting keratinocytes by inactivation of MALT1 paracaspase activity might be a promising therapeutic target for early psoriasis treatment.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Year:  2021        PMID: 33419765     DOI: 10.4049/jimmunol.2001031

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled From Effects on Regulatory T-Cells.

Authors:  Subhabrata Biswas; Aditi Chalishazar; Ynes Helou; Joanna DiSpirito; Brian DeChristopher; Devin Chatterjee; Leidy Merselis; Benjamin Vincent; John G Monroe; Dania Rabah; Andrew J Long
Journal:  Front Immunol       Date:  2022-05-09       Impact factor: 8.786

Review 2.  Gut Microbiota in Psoriasis.

Authors:  Mihaela Cristina Buhaș; Laura Ioana Gavrilaș; Rareș Candrea; Adrian Cătinean; Andrei Mocan; Doina Miere; Alexandru Tătaru
Journal:  Nutrients       Date:  2022-07-20       Impact factor: 6.706

3.  MALT1 reflects inflammatory cytokines, disease activity, and its chronological change could estimate treatment response to infliximab in Crohn's disease patients.

Authors:  Xiaoxia Dong; Xiaoxiao Chen; Yuxiu Ren
Journal:  J Clin Lab Anal       Date:  2022-08-29       Impact factor: 3.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.